

Marit A C Vermunt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3676010/publications.pdf>

Version: 2024-02-01

9
papers

57
citations

1684188
5
h-index

1720034
7
g-index

9
all docs

9
docs citations

9
times ranked

48
citing authors

#	ARTICLE	IF	CITATIONS
1	The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer, 2022, 22, 104.	2.6	3
2	Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients. Cancer Chemotherapy and Pharmacology, 2022, 89, 785-793.	2.3	5
3	A Phase 1 Dose Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors. Clinical Pharmacology in Drug Development, 2021, 10, 607-621.	1.6	7
4	Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours. Drugs in R and D, 2021, 21, 103-111.	2.2	4
5	<scp>ModraDoc006</scp>, an oral docetaxel formulation in combination with ritonavir (<scp>ModraDoc006</scp>/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. Cancer Reports, 2021, 4, e1367.	1.4	11
6	Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2021, 87, 855-869.	2.3	12
7	The intravenous to oral switch of taxanes: strategies and current clinical developments. Future Oncology, 2021, 17, 1379-1399.	2.4	7
8	Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials. Clinical Pharmacology: Advances and Applications, 2021, Volume 13, 21-32.	1.2	5
9	ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.. Journal of Clinical Oncology, 2020, 38, 79-79.	1.6	3